Uroxatral

Uroxatral,

a trademark for alfuzosin.

---

alfuzosin

Besavar (UK), Uroxatral, Xatral (CA) (UK)

Pharmacologic class: Alpha₁-adrenergic receptor blocker

Therapeutic class: Benign prostatic hyperplasia agent

Pregnancy risk category B

Action

Selectively inhibits alpha₁-adrenergic receptors in lower urinary tract, relaxing smooth muscle in bladder neck and prostate

Availability

Tablets (extended-release): 10 mg

⊘Indications and dosages

➣ Signs and symptoms of benign prostatic hyperplasia

Adults: 10 mg P.O. once daily with food, given at same meal each day

Contraindications

• Hypersensitivity to drug or its components
• Moderate or severe hepatic impairment
• Concomitant use of potent CYP-4503A4 inhibitors (such as itraconazole, ketoconazole, or ritonavir)

Precautions

Use cautiously until prostate cancer is ruled out. Also use cautiously in:
• coronary, hepatic, or renal insufficiency
• congenital or acquired QT prolongation.

Administration

• Administer with food.
• Don't crush or break tablet.

Route	Onset	Peak	Duration
P.O.	Unknown	8 hr	Unknown

Adverse reactions

CNS: dizziness, headache, fatigue

EENT: sinusitis, pharyngitis

GI: nausea, constipation, abdominal pain, dyspepsia

Respiratory: upper respiratory tract infection, bronchitis

Other: pain

Interactions

Drug-drug. Atenolol, cimetidine, diltiazem, itraconazole, ketoconazole, ritonavir: increased alfuzosin blood level

Drug-food. Any food: increased alfuzosin absorption

Patient monitoring

• Monitor patient for adverse reactions, such as dizziness.

Patient teaching

• Instruct patient to take drug with food at same time each day.
• Tell patient not to break, chew, or crush tablet.
• Caution patient to avoid driving and other hazardous activities until he knows if drug makes him dizzy.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and foods mentioned above.